Clinical Trials Directory

Trials / Unknown

UnknownNCT04101604

Biomarkers of Common Eye Diseases

Using Next-Generation Sequencing Technology to Identify Biomarkers of Common Eye Diseases

Status
Unknown
Phase
Study type
Observational
Enrollment
220 (estimated)
Sponsor
Sun Yat-sen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal vasculopathy. Our study may provide new insight into the underlying mechanisms, and reveal novel predictors and intervention targets for the diagnosis, prognosis and treatment of these diseases.

Detailed description

The pathogenesis of common eye diseases such as uveitis (including Behcet's disease (BD) and Vogt-Koyanagi-Harada disease (VKH)), diabetic retinopathy (DR), age-related macular degeneration (AMD) and polypoid choroidal vasculopathy (PCV) remains unknown. Although immunosuppressants, anti-vascular endothelial growth factor (VEGF) agents, and pars plana vitrectomy (PPV) have been widely used for treatment, the current therapeutic options are limited. In addition, there is a lack of biomarkers to indicate the prognosis and treatment response of these diseases. The aim of this study is to identify biomarkers and to provide a new target for individualized diagnosis and treatment of common eye diseases based on single cell sequencing technology.

Conditions

Interventions

TypeNameDescription
OTHERCollection of blood samplesCollection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.

Timeline

Start date
2019-09-26
Primary completion
2020-10-01
Completion
2021-10-01
First posted
2019-09-24
Last updated
2019-09-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04101604. Inclusion in this directory is not an endorsement.